Chronic daily headache: Transformational migraine, chronic migraine, and related disorders

Current Neurology and Neuroscience Reports

Volumn 8, Issue 2, 2008, Pages 100-107

  Saper, Joel R ^a  

^a Michigan Head Pain and Neurological Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; DIHYDROERGOTAMINE; DIPHENHYDRAMINE; ERGOT DERIVATIVE; GABAPENTIN; HYDROXYZINE; KETOROLAC; METOCLOPRAMIDE; NAPROXEN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; STEROID; TIZANIDINE; TOPIRAMATE; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ANXIETY DISORDER; BIPOLAR DISORDER; BLOOD ANALYSIS; BRADYCARDIA; CHOLINESTERASE INHIBITION; CHRONIC DAILY HEADACHE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DISEASE CONTROL; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG RESPONSE; FAMILY HISTORY; HOSPITALIZATION; HUMAN; HYPOTENSION; MAGNETIC RESONANCE ANGIOGRAPHY; NERVE STIMULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; PAIN; PANIC; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PSYCHOPATHY; REVIEW; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SUBSTANCE ABUSE; TACHYCARDIA; TRANSFORMED MIGRAINE; WEIGHT GAIN;

ANALGESICS, OPIOID; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS;

EID: 41549110249     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-008-0017-y     Document Type: Review

References (48)

1. Silberstein SD, Lipton RB, Dodick DW (editors): Wolff's Headache and Other Pain, edn 8. New York: Oxford University Press; 2008.
2. Scher AL, Stewart WF, Liberman J, Lipton RB: Prevalence of frequent headache in a population sample. Headache 1998, 38:497-506.
3. Wang SJ, Fuh JL, Lu SR, et al.: Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000, 54:314-319.
4. Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004, 24 (Suppl 1):9-160.
5. Mathew NT, Stubits E, Nigam MP: Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982, 22:66-68.
6. Saper JR, VanMeter MJ: Ergotamine addiction [abstract]. Presented at the American Association for the Study of Headache. San Francisco, CA; June, 1980.
7. Saper JR, Winters M, VanMeter MJ: Non-headache features of cluster headache [abstract]. Presented at the American Association for the Study of Headache. Washington, DC; June, 1981.
8. Saper JR: Headache Disorders: Current Concepts and Treatment Strategies. Boston: J. Wright-PSG Medical Publishers; 1983.
9. Silberstein SD, Lipton RB, Solomon S, Mathew NT: Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994, 34:1-7.
10. Saper JR, Jones JM: Ergotamine tartrate dependency: features and possible mechanisms. Clin J Neuropharmacol 1986, 9:244-256.
11. Headache Classification Committee: The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2006, 26:742-746.
12. Saper JR, Silberstein SD, Gordon CD, Hamel RL: Handbook of Headache Management, edn 2. Baltimore: Lippincott, Williams & Wilkins; 1999.
13. Saper JR, Dodick D, Gladstone JP: Management of chronic daily headache: challenges in clinical practice. Headache 2005, 45(Suppl 1):S74-S85.
14. Saper JR: Approach to the intractable headache case: identifying treatable barriers to improvement. Continuum: Lifelong Learning in Neurology 2006, 12:259-284.
15. Merikangas KR, Angst J, Isler H: Migraine and psychopathology: results of the Zurich cohort study of young adults. Arch Gen Psychiatry 1990, 47:849-853.
16. Breslau N, Davis GC: Migraine, physical health, and psychiatric disorders: a prospective epidemiologic study of young adults. J Psychiatric Res 1993, 27:211-221.
17. Mathew NT: Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache 1981, 21:105-109.
18. Mongini F, Defilippi N, Negro C: Chronic daily headache. A clinical and psychologic profile before and after treatment. Headache 1997, 37:83-87.
19. Lake AE, Saper JR, Hamel RL: Inpatient treatment of intractable headache: outcome for 267 consecutive program completers [abstract]. Headache 2006, 46:893.
20. Peres MF, Silberstein SD, Nahmias S, et al.: Hemicrania continua is not that rare. Neurology 2001, 57:948-951.
21. Granella F, Cavallini A, Sandrini G, et al.: Long-term outcome of migraine. Cephalalgia 1998, 18:30-33.
22. Scher AI, Lipton RB, Stewart W: Risk factors for chronic daily headache. Curr Pain Headache Rep 2002, 6:486-491.
23. Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81-89.
24. Bigal ME, Sheftell ED, Rapoport AM, et al.: Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002, 42:575-581.
25. Burstein R: Deconstructing migraine headache into a peripheral and central sensitization. Pain 2001, 89:107-110.
26. Watkins LR, Milligan ED, Maier SF: Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24:450-455.
27. Meng ID, Porreca F: Headache currents. Basic Science: mechanisms of medication overuse. Headache 2004, 1:47-54.
28. Mao J, Sung B, Ji RR, et al.: Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002, 22:7650-7661.
29. Saper JR, Hamel RL, Lake AE III: Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia 2005, 25:545-546.
30. Schwedt TJ, Dodick DW, Trentman TL, et al.: Occipital nerve stimulation for chronic cluster headache and hemicrania continua: pain relief and persistence of autonomic features. Cephalalgia 2006, 26:1025-1027.
31. Lim G, Wang S, Zeng Q, et al.: Evidence for long-term influence on morphine tolerance after previous morphine exposure: role of glucocorticoid receptors. Pain 2005, 114:81-92.
32. Saper JR, Lake AE III: Medication overuse headache: type I and type II [letter]. Cephalalgia 2006, 26:1262.
33. Ozyalcin SN, Talu GK, Kizitan E, et al.: The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005, 45:144-152.
34. Jensen R, Brinck T, Olesen J: Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994, 44:647-651.
35. Mathew NT, Saper JR, Silberstein SD, et al.: Migraine prophylaxis with divalproex. Arch Neurol 1995, 52:281-286.
36. Freitag FG, Diamond S, Diamond M, et al.: Divalproex in the long-term treatment of chronic daily headache. Headache 2001, 41:271-278.
37. Spira PJ, Beran RG: Gabapentin in the prophylaxis of chronic daily headache. A randomized, placebo-controlled study for the Australian Gabapentin Chronic Daily Headache Group. Neurology 2003, 61:1753-1759.
38. Silberstein SD, Neto W, Schmitt J, et al.: Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. MIGR-001 Study Group. Arch Neurol 2004, 61:490-495.
39. Brandes JL, Saper JR, Diamond M, et al.: Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004, 291:965-973.
40. Mathew NT, Schmit TJ, Jacobs D, et al.: Topiramate in migraine prevention (MIGR-001): effect on migraine frequency [abstract]. Neurology 2003, 60:A336.
41. Silberstein S, Lipton RB, Dodick DW, et al.: Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007, 47:170-180.
42. Saper JR, Lake AE III, Cantrell DT, et al.: Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002, 42:470-482.
43. Mauskop A: Botulinum toxin in the treatment of chronic daily headache [abstract]. Cephalalgia 1999, 19:453.
44. Dodick DW, Mauskop A, Elkind AH, et al.: Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized, double-blind, placebo-controlled study. Headache 2005, 45:315-324.
45. Silberstein SD, Stark SR, Lucas SM, et al.: Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:1126-1137.
46. Saper JR, Lake AE III, Hamel RL, et al.: Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology 2004, 62:1687-1694.
47. Saper JR, Lake AE, Madden SF, et al.: Comprehensive/tertiary care for headache: a 6-month outcome study. Headache 1999, 39:249-263.
48. Freitag FG, Lake AE III, Lipton R, et al.: Inpatient treatment of headache: an evidence-based assessment. Headache 2004, 44:342-360.